Literature DB >> 31777260

MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.

Y Zuo1,2, W Zheng2, J Liu2, Q Tang2, S S Wang2, X S Yang1.   

Abstract

Ovarian cancer is the most lethal gynecologic malignancy in women with an increasing number of cases worldwide. Chemoresistance is the main obstacle for ovarian cancer treatment during clinical therapy. Previous studies found that programmed cell death 1 ligand 1 (PD-L1) was associated with chemoresistance of cancer. However, there were little reports about the function of PD-L1 involved in chemoresistance of ovarian cancer. In our study, cisplatin (DDP)-resistant SKOV3 and A2780 ovarian cancer cell lines (SKOV3/DDP and A2780/DDP) were established. We found that the expression of PD-L1 was increased and miR-34a-5p was decreased in DDP-resistant cells. PD-L1 silencing inhibited chemoresistance of DDP-resistant ovarian cancer cells to DDP, as evidenced by decreased proliferation, G1-phase cell cycle arrest and increased apoptosis. Western blot assay showed that in the presence of DDP, PD-L1 silencing decreased multidrug resistance protein 1 and Cyclin D1 protein levels, whereas increased cleaved-caspase-3 and cleaved-PARP protein levels in these cells. Moreover, we demonstrated that miR-34a-5p negatively regulated the expression of PD-L1 by targeting its 3'-untranslated region. The effects of miR-34a-5p mimic on DDP-treated SKOV3/DDP cells were reversed by the overexpression of PD-L1. Moreover, the tumorigenicity of DDP-resistant ovarian cancer cells in nude mice treated with DDP was attenuated by miR-34a-5p in vivo. The combined data indicate that miR-34a-5p/PD-L1 axis regulates DDP chemoresistance of ovarian cancer cells, providing a deeper insight into the treatment for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31777260     DOI: 10.4149/neo_2019_190202N106

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  23 in total

1.  Silencing of Long Non-coding RNA LINC01106 Represses Malignant Behaviors of Gastric Cancer Cells by Targeting miR-34a-5p/MYCN Axis.

Authors:  Sen Hong; Qiuxia Li; Ying Yang; Deqian Jing; Fengbo Zhu
Journal:  Mol Biotechnol       Date:  2021-09-22       Impact factor: 2.695

2.  IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.

Authors:  Sveta Padmanabhan; Bijaya Gaire; Yue Zou; Mohammad M Uddin; Ivana Vancurova
Journal:  Cell Signal       Date:  2022-07-09       Impact factor: 4.850

Review 3.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

4.  AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells.

Authors:  Haijing Wang; Disong Wang; Tingting Gu; Mengjiao Zhu; Ling Cheng; Wentao Dai
Journal:  Histol Histopathol       Date:  2022-04-22       Impact factor: 2.130

5.  Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.

Authors:  Yun Zhang; Hao Ai; Xue Fan; Suxian Chen; Yadi Wang; Lili Liu
Journal:  Biol Res       Date:  2020-04-29       Impact factor: 5.612

6.  Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.

Authors:  Xun Wu; Yi-Shing Lisa Cheng; Mathew Matthen; Angela Yoon; Gary K Schwartz; Shashi Bala; Alison M Taylor; Fatemeh Momen-Heravi
Journal:  J Exp Clin Cancer Res       Date:  2021-02-17

7.  Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC).

Authors:  Chunfeng Li; Junqiang Qiu; Yingwei Xue
Journal:  Cell Biosci       Date:  2021-02-12       Impact factor: 7.133

8.  Systemic Analysis of the DNA Replication Regulator MCM Complex in Ovarian Cancer and Its Prognostic Value.

Authors:  Yukun Li; Juan Zou; Qunfeng Zhang; Feifei Quan; Lu Cao; Xiaodi Zhang; Jue Liu; Daichao Wu
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

9.  LINC00665/miR-379-5p/GRP78 regulates cisplatin sensitivity in gastric cancer by modulating endoplasmic reticulum stress.

Authors:  Chao Yue; Chen Yu; Rui Peng; Jian Wang; Gang Li; Lin Xu
Journal:  Cytotechnology       Date:  2021-04-26       Impact factor: 2.040

10.  Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.

Authors:  Xuan Feng; Feng Xue; Guihua He; Qing Ni; Suiping Huang
Journal:  Int J Mol Med       Date:  2021-07-19       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.